Sitagliptin, the first approved DPP-4 inhibitor considered to have fewer side effects than metformin, is firmly established as important mono- or combination therapy (with other anti-hyperglycemic drugs) in T2DM adult patients[13]. This evidence concerns the gene DPP4 and type 2 diabetes mellitus.